1233533-04-4

Basic information

• Product Name: 3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one
• Synonyms: 3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one;kb-NB142-70 3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one
• CAS NO: 1233533-04-4
• Molecular Formula: C11H9NO2S2
• Molecular Weight: 251.32466
• Product Categories: Inhibitors
• Mol File: 1233533-04-4.mol

Chemical Properties

• Melting Point: 235-238℃ (decomposition) (water dichloromethane )
• Boiling Point: 601.9±55.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.495±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble10mg/mL, clear
• PKA: 8.99±0.20(Predicted)
• CAS DataBase Reference: 3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one(1233533-04-4)
• EPA Substance Registry System: 3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one(1233533-04-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1233533-04-4(Hazardous Substances Data)

Usage

Uses

kb NB 142-70 is a potent & selective protein kinase D inhibitor.

Upstream product

• 122024-75-3 C₁₆H₁₄O₃ 
• 1259977-93-9 methyl 5-(benzyloxy)-3-chlorobenzo[b]thiophene-2-carboxylate 
• 1259977-97-3 kb-NB₁₂₃-66 
• 14755-02-3 3-hydroxycinnamic acid 
• 122024-71-9 3-Chloro-5-(phenylmethoxy)-benzo[b]thiophene-2-carbonyl chloride 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 122024-75-3 3-<3-(phenylmethoxy)phenyl>-2-propenoic acid 

Downstream Products

• 172832-10-9 3,4-dihydro-9-methoxy[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one 

Relevant articles and documents

PROTEIN KINASE D INHIBITORS

Compounds according to Formula (I), are potent inhibitors of protein kinase D (pan-PKD) activity. PKD controls key signaling cascades in cells, affecting cell proliferation, gene transcription, and protein trafficking. Accordingly, pharmaceutically acceptable compositions of the inventive compounds are candidate therapeutics for pathological conditions conditioned by changes in PKD activity.

Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of protein kinase D

Protein kinase D (PKD) is a member of a novel family of serine/threonine kinases that regulate fundamental cellular processes. PKD is implicated in the pathogenesis of several diseases, including cancer. Progress in understanding the biological functions and therapeutic potential of PKD has been hampered by the lack of specific inhibitors. The benzoxoloazepinolone CID755673 was recently identified as the first potent and selective PKD inhibitor. The study of structure-activity relationships (SAR) of this lead compound led to further improvements in PKD1 potency. We describe herein the synthesis and biological evaluation of novel benzothienothiazepinone analogues. We achieved a 10-fold increase in the in vitro PKD1 inhibitory potency for the second generation lead kb-NB142-70 and accomplished a transition to an almost equally potent novel pyrimidine scaffold, while maintaining excellent target selectivity. These promising results will guide the design of pharmacological tools to dissect PKD function and pave the way for the development of potential anticancer agents.